CoChat

The Impact of Inherited Retinal Diseases in the United States of America (US) and Canada from a Cost-of-Illness Perspective

Open access

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To estimate the annual cost of inherited retinal diseases (IRDs) in the United States of America (US) and Canada from a societal perspective - including costs to the health system, individual and family productivity costs, lost wellbeing and other societal economic costs - by setting and payer. Findings will inform the need for policy action to mitigate the impact of IRDs. METHODS: The costs of IRDs were estimated using a cost-of-illness methodology, based on the prevalence of IRDs in each country. Intangible costs of reduced wellbeing were also estimated using disability-adjusted life years which were then converted to monetary values using the value of a statistical life. RESULTS: Using base prevalence rates, total costs attributable to IRDs in the US were estimated to range between US$13,414.0 and US$31,797.4 million in 2019, comprising both economic costs (between US$4,982 and US$11,753.9 million; 37% of total costs) and wellbeing costs (between US$8,431.7 and US$20,043.6 million; 63%). Total costs attributable to IRDs in Canada were estimated to range between CAN$1637.8 and CAN$6687.5 million in 2019, comprising both economic costs (between CAN$566.6 and CAN$2,305.7 million; 34%) and wellbeing costs (between CAN$1,071.4 and CAN$4,381.9 million; 66% of total costs). CONCLUSION: The impact of IRDs in the US and Canada is substantial when considering both economic costs and reduced wellbeing. The wellbeing costs due to IRDs in the US and Canada are considerable, accounting for over 60% of total costs. Vision loss from IRDs often manifests in childhood, meaning some people live with vision impairment and blindness for their whole lives. Further research into current and emerging cost-effective therapies and interventions is required given the substantial economic burden faced by those living with vision loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/opth.s313719

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Proportion (%) of total costs of IRDs in Canada (A) and the US (B) by cost type in 2019.
Figure 1 Proportion (%) of total costs of IRDs in Canada (A) and the US (B) by cost type in 2019.CC BY-NC · PubMed Central
Figure 2 Proportion (%) of total costs of IRDs in Canada (A) and the US (B) by payer in 2019.
Figure 2 Proportion (%) of total costs of IRDs in Canada (A) and the US (B) by payer in 2019.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 5

  1. Mayro, 2020, Eur J Ophthalmol, 1
  2. Fullerton, 2017, Natl Bureau Econ Res
  3. Baicker, 2011, Natl Bur Econ Res Bull Aging Health, 25, 39
  4. Canadian Arthritis Network. Canadian Arthritis Funding Landscape Review. Available from: https://www.arthrite.ca/AS/media/pdf/Researchers/Arthritis-Funding-Final-Final-Landscape-Review.pdf. Accessed March 10, 2021.
  5. Petty, 2004, J Rheumatol, 31, 390

Cited by

See all 70

Metadata

Authors
Gong, J., Cheung, S., Fasso-Opie, A., Galvin, O., Moniz, L. S., Earle, D., Durham, T., Menzo, J., Li, N., Duffy, S., Dolgin, J., Shearman, M. S., Fiorani, C., Banhazi, J., & Daly, A.
Affiliations
  • Foundation Fighting Blindness (US)
  • Applied Genetic Technologies (United States) (US)
  • Novartis (Switzerland) (CH)
Corresponding author
Daly, Avril
Venue
Clinical Ophthalmology
Published
2021-07
Volume
Volume 15
Pages
2855-2866
ISSN
  • 1177-5467 (ISSN-L)
  • 1177-5483
OpenAlex
W3175694094
Cited by
64
References
19
Citations by year
2026: 9 · 2025: 18 · 2024: 17 · 2023: 14 · 2022: 6
FWCI
7.06
Type
journal article
Language
en
Open access
Locations
  • Clinical ophthalmology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
inherited retinal disease, economic burden, disability-adjusted life years, value of a statistical life, vision loss, productivity costs, health system costs, blindness, prevalence, United States, Canada

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Impact of Inherited Retinal Diseases in the United States of America (US) and Canada from a Cost-of-Illness Perspective. https://app.cochat.ai/papers/10.2147/opth.s313719
The paper
Gong, J., Cheung, S., Fasso-Opie, A., Galvin, O., Moniz, L. S., Earle, D., Durham, T., Menzo, J., Li, N., Duffy, S., Dolgin, J., Shearman, M. S., Fiorani, C., Banhazi, J., & Daly, A. (2021). The Impact of Inherited Retinal Diseases in the United States of America (US) and Canada from a Cost-of-Illness Perspective. Clinical Ophthalmology. https://doi.org/10.2147/opth.s313719

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.